LOOKING FOR ASSISTANCE WITH ANALYZING AND INTERPRETING YOUR DATA?
AltraBio is a contract research company specializing in the analysis of biological and medical data using statistical methods and artificial intelligence.
Trusted globally, AltraBio serves as a research and development partner for leading companies and university hospitals across pharmaceuticals, medical devices, diagnostics, and dermato-cosmetics sectors.
How can we work together?
Partnership
Development of computational tools for data analysis in regional / national / international consortia.
Examples of current and completed projects:
Subcontracting
Data analysis for companies and university hospitals.
-
Hundreds of completed projects
-
Regular customers including top 10 pharmas and leaders in cosmetics
Funding
NEWS
May 2024
18th WRIB
🔬 AltraBio is thrilled to announce our participation at [...]
April 2024
CYTO 2024
🔬 AltraBio is thrilled to announce our participation at [...]
January 2024
Conference I3M
We are delighted to announce our presence at the [...]
November 2023
Immunotherapies & Innovations for Infectious Diseases
AltraBio is delighted to announce its presence at the next I4ID [...]
LATEST PUBLICATIONS
2022
Silic, Linda Ljungberg; Lefevre, Marine-Alexia; Bergendorff, Ola; Bernard, Simon De; Nourikyan, Julien; Buffat, Laurent; Nosbaum, Audrey; Bruze, Magnus; cois Nicolas, Jean-Franc; Svedman, Cecilia; Vocanson, Marc
Gene profiling reveals a contact allergy signature in most positive Amerchol L-101 patch test reactions Journal Article
In: Contact Dermatitis, vol. 87, no. 1, pp. 40–52, 2022.
@article{Silic2022,
title = {Gene profiling reveals a contact allergy signature in most positive Amerchol L-101 patch test reactions},
author = {Linda Ljungberg Silic and Marine-Alexia Lefevre and Ola Bergendorff and Simon De Bernard and Julien Nourikyan and Laurent Buffat and Audrey Nosbaum and Magnus Bruze and Jean-Franc cois Nicolas and Cecilia Svedman and Marc Vocanson},
year = {2022},
date = {2022-07-01},
urldate = {2022-07-01},
journal = {Contact Dermatitis},
volume = {87},
number = {1},
pages = {40--52},
publisher = {Wiley},
abstract = {BACKGROUND: Diagnosis of contact allergy (CA) to Amerchol L-101
(AL-101), a marker for lanolin allergy, is problematic. Positive
patch test reactions are frequently doubtful or weakly positive
and difficult to associate with clinical relevance. OBJECTIVE:
To gain further insight on the allergic or irritant nature of
skin reactions induced by AL-101 patch test. METHODS: We
re-tested in a dose-response fashion, 10 subjects with AL-101 CA
and performed comprehensive transcriptomic analysis (gene
arrays, quantitative real-time polymerase chain reaction
[qRT-PCR]) of samples of their skin reactions. RESULTS: Eight of
the 10 CA subjects reacted positively upon re-test, whereas two
did not react. Most of AL-101 positive patch tests expressed an
allergy signature with strong activation of gene modules
associated with adaptive immunity and downregulation of
cornification pathway genes. In addition, the breadth of gene
modulation correlated with the magnitude of patch test reactions
and the concentration of AL-101 applied. However, we observed
that some of the positive patch test reactions to AL-101
expressed no/few allergy biomarkers, suggesting the induction of
an irritant skin inflammation in these samples. CONCLUSIONS:
This study confirms that AL-101 is an allergen that can cause
both contact allergy and contact irritation. Our results also
highlight that molecular profiling might help to strengthen
clinical diagnosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Diagnosis of contact allergy (CA) to Amerchol L-101
(AL-101), a marker for lanolin allergy, is problematic. Positive
patch test reactions are frequently doubtful or weakly positive
and difficult to associate with clinical relevance. OBJECTIVE:
To gain further insight on the allergic or irritant nature of
skin reactions induced by AL-101 patch test. METHODS: We
re-tested in a dose-response fashion, 10 subjects with AL-101 CA
and performed comprehensive transcriptomic analysis (gene
arrays, quantitative real-time polymerase chain reaction
[qRT-PCR]) of samples of their skin reactions. RESULTS: Eight of
the 10 CA subjects reacted positively upon re-test, whereas two
did not react. Most of AL-101 positive patch tests expressed an
allergy signature with strong activation of gene modules
associated with adaptive immunity and downregulation of
cornification pathway genes. In addition, the breadth of gene
modulation correlated with the magnitude of patch test reactions
and the concentration of AL-101 applied. However, we observed
that some of the positive patch test reactions to AL-101
expressed no/few allergy biomarkers, suggesting the induction of
an irritant skin inflammation in these samples. CONCLUSIONS:
This study confirms that AL-101 is an allergen that can cause
both contact allergy and contact irritation. Our results also
highlight that molecular profiling might help to strengthen
clinical diagnosis.
(AL-101), a marker for lanolin allergy, is problematic. Positive
patch test reactions are frequently doubtful or weakly positive
and difficult to associate with clinical relevance. OBJECTIVE:
To gain further insight on the allergic or irritant nature of
skin reactions induced by AL-101 patch test. METHODS: We
re-tested in a dose-response fashion, 10 subjects with AL-101 CA
and performed comprehensive transcriptomic analysis (gene
arrays, quantitative real-time polymerase chain reaction
[qRT-PCR]) of samples of their skin reactions. RESULTS: Eight of
the 10 CA subjects reacted positively upon re-test, whereas two
did not react. Most of AL-101 positive patch tests expressed an
allergy signature with strong activation of gene modules
associated with adaptive immunity and downregulation of
cornification pathway genes. In addition, the breadth of gene
modulation correlated with the magnitude of patch test reactions
and the concentration of AL-101 applied. However, we observed
that some of the positive patch test reactions to AL-101
expressed no/few allergy biomarkers, suggesting the induction of
an irritant skin inflammation in these samples. CONCLUSIONS:
This study confirms that AL-101 is an allergen that can cause
both contact allergy and contact irritation. Our results also
highlight that molecular profiling might help to strengthen
clinical diagnosis.
Silic, Linda Ljungberg; Lefevre, Marine-Alexia; Bergendorff, Ola; Bernard, Simon De; Nourikyan, Julien; Buffat, Laurent; Nosbaum, Audrey; Bruze, Magnus; Nicolas, Jean-François; Svedman, Cecilia; Vocanson, Marc
Gene profiling reveals a contact allergy signature in most positive Amerchol L-101 patch test reactions Journal Article
In: Contact Dermatitis, vol. 87, no. 1, pp. 40–52, 2022, ISSN: 1600-0536.
@article{pmid35184302,
title = {Gene profiling reveals a contact allergy signature in most positive Amerchol L-101 patch test reactions},
author = {Linda Ljungberg Silic and Marine-Alexia Lefevre and Ola Bergendorff and Simon De Bernard and Julien Nourikyan and Laurent Buffat and Audrey Nosbaum and Magnus Bruze and Jean-François Nicolas and Cecilia Svedman and Marc Vocanson},
doi = {10.1111/cod.14077},
issn = {1600-0536},
year = {2022},
date = {2022-07-01},
urldate = {2022-07-01},
journal = {Contact Dermatitis},
volume = {87},
number = {1},
pages = {40--52},
abstract = {BACKGROUND: Diagnosis of contact allergy (CA) to Amerchol L-101 (AL-101), a marker for lanolin allergy, is problematic. Positive patch test reactions are frequently doubtful or weakly positive and difficult to associate with clinical relevance.
OBJECTIVE: To gain further insight on the allergic or irritant nature of skin reactions induced by AL-101 patch test.
METHODS: We re-tested in a dose-response fashion, 10 subjects with AL-101 CA and performed comprehensive transcriptomic analysis (gene arrays, quantitative real-time polymerase chain reaction [qRT-PCR]) of samples of their skin reactions.
RESULTS: Eight of the 10 CA subjects reacted positively upon re-test, whereas two did not react. Most of AL-101 positive patch tests expressed an allergy signature with strong activation of gene modules associated with adaptive immunity and downregulation of cornification pathway genes. In addition, the breadth of gene modulation correlated with the magnitude of patch test reactions and the concentration of AL-101 applied. However, we observed that some of the positive patch test reactions to AL-101 expressed no/few allergy biomarkers, suggesting the induction of an irritant skin inflammation in these samples.
CONCLUSIONS: This study confirms that AL-101 is an allergen that can cause both contact allergy and contact irritation. Our results also highlight that molecular profiling might help to strengthen clinical diagnosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Diagnosis of contact allergy (CA) to Amerchol L-101 (AL-101), a marker for lanolin allergy, is problematic. Positive patch test reactions are frequently doubtful or weakly positive and difficult to associate with clinical relevance.
OBJECTIVE: To gain further insight on the allergic or irritant nature of skin reactions induced by AL-101 patch test.
METHODS: We re-tested in a dose-response fashion, 10 subjects with AL-101 CA and performed comprehensive transcriptomic analysis (gene arrays, quantitative real-time polymerase chain reaction [qRT-PCR]) of samples of their skin reactions.
RESULTS: Eight of the 10 CA subjects reacted positively upon re-test, whereas two did not react. Most of AL-101 positive patch tests expressed an allergy signature with strong activation of gene modules associated with adaptive immunity and downregulation of cornification pathway genes. In addition, the breadth of gene modulation correlated with the magnitude of patch test reactions and the concentration of AL-101 applied. However, we observed that some of the positive patch test reactions to AL-101 expressed no/few allergy biomarkers, suggesting the induction of an irritant skin inflammation in these samples.
CONCLUSIONS: This study confirms that AL-101 is an allergen that can cause both contact allergy and contact irritation. Our results also highlight that molecular profiling might help to strengthen clinical diagnosis.
OBJECTIVE: To gain further insight on the allergic or irritant nature of skin reactions induced by AL-101 patch test.
METHODS: We re-tested in a dose-response fashion, 10 subjects with AL-101 CA and performed comprehensive transcriptomic analysis (gene arrays, quantitative real-time polymerase chain reaction [qRT-PCR]) of samples of their skin reactions.
RESULTS: Eight of the 10 CA subjects reacted positively upon re-test, whereas two did not react. Most of AL-101 positive patch tests expressed an allergy signature with strong activation of gene modules associated with adaptive immunity and downregulation of cornification pathway genes. In addition, the breadth of gene modulation correlated with the magnitude of patch test reactions and the concentration of AL-101 applied. However, we observed that some of the positive patch test reactions to AL-101 expressed no/few allergy biomarkers, suggesting the induction of an irritant skin inflammation in these samples.
CONCLUSIONS: This study confirms that AL-101 is an allergen that can cause both contact allergy and contact irritation. Our results also highlight that molecular profiling might help to strengthen clinical diagnosis.
Bonduelle, Olivia; Chaudesaigues, Chloé; Tolazzi, Monica; Suleiman, Ehsan; Bernard, Simon; Alves, Karine; Nourikyan, Julien; Bohec, Mylene; Baudrin, Laura G; Katinger, Dietmar; Debré, Patrice; Scarlatti, Gabriella; Vieillard, Vincent; Combadi`ere, Behazine
Dichotomy in neutralizing antibody induction to peptide-conjugated vaccine in squalene emulsion contrast with aluminum hydroxide formulation Journal Article
In: Front. Immunol., vol. 13, pp. 848571, 2022.
@article{pmid35464449,
title = {Dichotomy in neutralizing antibody induction to peptide-conjugated vaccine in squalene emulsion contrast with aluminum hydroxide formulation},
author = {Olivia Bonduelle and Chloé Chaudesaigues and Monica Tolazzi and Ehsan Suleiman and Simon Bernard and Karine Alves and Julien Nourikyan and Mylene Bohec and Laura G Baudrin and Dietmar Katinger and Patrice Debré and Gabriella Scarlatti and Vincent Vieillard and Behazine Combadi`ere},
doi = {10.3389/fimmu.2022.848571},
year = {2022},
date = {2022-04-01},
urldate = {2022-04-01},
journal = {Front. Immunol.},
volume = {13},
pages = {848571},
publisher = {Frontiers Media SA},
abstract = {W614A-3S peptide is a modified 3S motif of the HIV-gp41
(mutation W614A). We previously detected the presence of natural
neutralizing antibodies directed against W614A-3S peptide (NAbs)
in long-term non-progressor HIV+ patients. Here, we compared the
efficacy of W614A-3S peptide formulated in either squalene
emulsion (SQE) or in aluminum hydroxide (Alum) in inducing
broadly-NAbs (bNAbs). Rabbit and mouse models were used to
screen the induction of bNAbs following 4 immunizations. SQE was
more efficient than Alum formulation in inducing
W614A-3S-specific bNAbs with up to 67%-93% of HIV strains
neutralized. We then analyzed the quality of peptide-specific
murine B cells by single-cell gene expression by quantitative
reverse transcription-PCR and single-cell V(D)J sequencing. We
found more frequent germinal center B cells in SQE than in Alum,
albeit with a different gene expression profile. The V(D)J
sequencing of W614A-3S-specific BCR showed significant
differences in BCR sequences and validates the dichotomy between
adjuvant formulations. All sixteen BCR sequences which were
cloned were specific of peptide. Adjuvant formulations of
W614A-3S-peptide-conjugated immunogen impact the quantity and
quality of B cell immune responses at both the gene expression
level and BCR sequence.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
W614A-3S peptide is a modified 3S motif of the HIV-gp41
(mutation W614A). We previously detected the presence of natural
neutralizing antibodies directed against W614A-3S peptide (NAbs)
in long-term non-progressor HIV+ patients. Here, we compared the
efficacy of W614A-3S peptide formulated in either squalene
emulsion (SQE) or in aluminum hydroxide (Alum) in inducing
broadly-NAbs (bNAbs). Rabbit and mouse models were used to
screen the induction of bNAbs following 4 immunizations. SQE was
more efficient than Alum formulation in inducing
W614A-3S-specific bNAbs with up to 67%-93% of HIV strains
neutralized. We then analyzed the quality of peptide-specific
murine B cells by single-cell gene expression by quantitative
reverse transcription-PCR and single-cell V(D)J sequencing. We
found more frequent germinal center B cells in SQE than in Alum,
albeit with a different gene expression profile. The V(D)J
sequencing of W614A-3S-specific BCR showed significant
differences in BCR sequences and validates the dichotomy between
adjuvant formulations. All sixteen BCR sequences which were
cloned were specific of peptide. Adjuvant formulations of
W614A-3S-peptide-conjugated immunogen impact the quantity and
quality of B cell immune responses at both the gene expression
level and BCR sequence.
(mutation W614A). We previously detected the presence of natural
neutralizing antibodies directed against W614A-3S peptide (NAbs)
in long-term non-progressor HIV+ patients. Here, we compared the
efficacy of W614A-3S peptide formulated in either squalene
emulsion (SQE) or in aluminum hydroxide (Alum) in inducing
broadly-NAbs (bNAbs). Rabbit and mouse models were used to
screen the induction of bNAbs following 4 immunizations. SQE was
more efficient than Alum formulation in inducing
W614A-3S-specific bNAbs with up to 67%-93% of HIV strains
neutralized. We then analyzed the quality of peptide-specific
murine B cells by single-cell gene expression by quantitative
reverse transcription-PCR and single-cell V(D)J sequencing. We
found more frequent germinal center B cells in SQE than in Alum,
albeit with a different gene expression profile. The V(D)J
sequencing of W614A-3S-specific BCR showed significant
differences in BCR sequences and validates the dichotomy between
adjuvant formulations. All sixteen BCR sequences which were
cloned were specific of peptide. Adjuvant formulations of
W614A-3S-peptide-conjugated immunogen impact the quantity and
quality of B cell immune responses at both the gene expression
level and BCR sequence.